Our broad and varied portfolio and years of experience allow us to offer modern products and solutions to pharmaceutical companies worldwide. About 20% of the substances we manufacture are used for the production of our own finished drug forms. The rest is intended for external companies, 95% of which is exported, mainly to other EU countries and to North America, Latin America, North Africa, Korea and Japan. We are present on 6 continents, and our market position is growing.
The total capacity of our reactors for substance synthesis is 350,000 litres. Our manufacturing facilities are subject to rigorous inspections by the US Food and Drug Administration (FDA). All FDA inspections (in 2004, 2009, 2012 and 2015) conducted so far have resulted in no objections being raised.
For more information log on to www.api.polpharma.com
For any inquiries on contract manufacturing, please e-mail: email@example.com